Wim Goettsch

7.0k total citations · 3 hit papers
146 papers, 4.6k citations indexed

About

Wim Goettsch is a scholar working on Economics and Econometrics, General Health Professions and Physiology. According to data from OpenAlex, Wim Goettsch has authored 146 papers receiving a total of 4.6k indexed citations (citations by other indexed papers that have themselves been cited), including 98 papers in Economics and Econometrics, 23 papers in General Health Professions and 17 papers in Physiology. Recurrent topics in Wim Goettsch's work include Health Systems, Economic Evaluations, Quality of Life (94 papers), Pharmaceutical Economics and Policy (66 papers) and Healthcare cost, quality, practices (18 papers). Wim Goettsch is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (94 papers), Pharmaceutical Economics and Policy (66 papers) and Healthcare cost, quality, practices (18 papers). Wim Goettsch collaborates with scholars based in Netherlands, United Kingdom and United States. Wim Goettsch's co-authors include Ron M. C. Herings, Amr Makady, Olaf H. Klungel, Anthonius de Boer, Hans L. Hillege, Sebastian Schneeweiß, Rick A. Vreman, Shirley Wang, M Sprenger and Hubert G. M. Leufkens and has published in prestigious journals such as SHILAP Revista de lepidopterología, Annals of Internal Medicine and PLoS ONE.

In The Last Decade

Wim Goettsch

139 papers receiving 4.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The Relationship between Antimicrobial Use and Antimicrobial Resistance in Europe

2002 536 citations Wim Goettsch et al. profile →
Good Practices for Real‐World Data Studies of Treatment and/or Comparative Effectiveness: Recommendations from the Joint ISPOR‐ISPE Special Task Force on Real‐World Evidence in Health Care Decision Making

2017 327 citations Wim Goettsch, Amr Makady et al. Value in Health profile →
What Is Real-World Data? A Review of Definitions Based on Literature and Stakeholder Interviews

2017 226 citations Amr Makady, Anthonius de Boer et al. Value in Health profile →

Peers

Wim Goettsch

EPIDE

SURGE

GHP

PRM

Richard J. Willke United States

Mark G. Weiner United States

Aukje K. Mantel‐Teeuwisse Netherlands

Sean Hennessy United States

Jan Beyersmann Germany

Brian C. Sauer United States

Kevin Haynes United States

Rosanna Tarricone Italy

Nirav R. Shah United States

K. Arnold Chan United States

Richard J. Willke United States

Wim Goettsch

2.0k ×1.2

447 ×0.6

EPIDE

364 ×0.7

SURGE

1.0k ×2.2

GHP

270 ×0.6

PRM

Citations per year, relative to Wim Goettsch Wim Goettsch (= 1×) peers Richard J. Willke

Countries citing papers authored by Wim Goettsch

Since Specialization

Citations

This map shows the geographic impact of Wim Goettsch's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Wim Goettsch with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Wim Goettsch more than expected).

Fields of papers citing papers by Wim Goettsch

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Wim Goettsch. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Wim Goettsch. The network helps show where Wim Goettsch may publish in the future.

Co-authorship network of co-authors of Wim Goettsch

This figure shows the co-authorship network connecting the top 25 collaborators of Wim Goettsch. A scholar is included among the top collaborators of Wim Goettsch based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Wim Goettsch. Wim Goettsch is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Hernando, M. Elena, Junfeng Wang, Wim Goettsch, et al.. (2025). Prediction of glycaemic control and quality of life in people with type 2 diabetes using glucose‐lowering drugs with machine learning—The Maastricht study. Diabetes Obesity and Metabolism. 27(10). 5524–5537.

Shea, Beverley, Jordi Pardo Pardo, Dorcas Beaton, et al.. (2024). Increasing uptake through collaboration in the development of core outcome sets: Lessons learned at OMERACT 2023. Seminars in Arthritis and Rheumatism. 66. 152438–152438.

Mol, Peter G. M., Walter Van Dyck, Anja Schiel, et al.. (2024). Navigating the path towards successful implementation of the EU HTA Regulation: key takeaways from the 2023 Spring Convention of the European Access Academy. Health Research Policy and Systems. 22(1). 74–74. 7 indexed citations

García-Sáez, Gema, M. Elena Hernando, Junfeng Wang, et al.. (2024). Disease severity-based subgrouping of type 2 diabetes does not parallel differences in quality of life: the Maastricht Study. Diabetologia. 67(4). 690–702. 4 indexed citations

Elvidge, Jamie, Saskia Knies, Bertalan Németh, et al.. (2023). Health technology assessment of tests for SARS-CoV-2 and treatments for COVID-19: A proposed approach and best-practice recommendations. International Journal of Technology Assessment in Health Care. 39(1). e24–e24. 4 indexed citations

Zuidgeest, Mira G. P., Yared Santa‐Ana‐Téllez, Wim Goettsch, et al.. (2023). Opportunities and Challenges for Decentralized Clinical Trial Approaches: European Health Technology Assessment Perspective. Value in Health. 27(3). 294–300. 11 indexed citations

Németh, Bertalan, Maria Kamusheva, Antal Zemplényi, et al.. (2023). Guidance on using real-world evidence from Western Europe in Central and Eastern European health policy decision making. Journal of Comparative Effectiveness Research. 12(4). e220157–e220157. 2 indexed citations

Vreman, Rick A., Anna Zawada, Magdalena Zielińska, et al.. (2023). Synergy between health technology assessments and clinical guidelines for multiple sclerosis. Clinical and Translational Science. 16(5). 835–849. 6 indexed citations

Vreman, Rick A., Junfeng Wang, Marie L. De Bruin, et al.. (2023). Perspectives on how to build bridges between regulation, health technology assessment and clinical guideline development: a qualitative focus group study with European experts. BMJ Open. 13(8). e072309–e072309. 10 indexed citations

10.

Vreman, Rick A., et al.. (2022). When Reality Does Not Meet Expectations—Experiences and Perceived Attitudes of Dutch Stakeholders Regarding Payment and Reimbursement Models for High-Priced Hospital Drugs. International Journal of Environmental Research and Public Health. 20(1). 340–340. 9 indexed citations

11.

Vreman, Rick A., et al.. (2022). Addressing uncertainty in relative effectiveness assessments by HTA organizations. International Journal of Technology Assessment in Health Care. 38(1). e17–e17. 7 indexed citations

12.

Vreman, Rick A., et al.. (2021). Bridging the gap: Can International Consortium of Health Outcomes Measurement standard sets align outcomes accepted for regulatory and health technology assessment decision‐making of oncology medicines. Pharmacology Research & Perspectives. 9(2). e00742–e00742. 8 indexed citations

13.

Vreman, Rick A., et al.. (2020). The Application and Implications of Novel Deterministic Sensitivity Analysis Methods. PharmacoEconomics. 39(1). 1–17. 21 indexed citations

14.

Németh, Bertalan, Wim Goettsch, Finn Børlum Kristensen, et al.. (2020). The transferability of health technology assessment: the European perspective with focus on central and Eastern European countries. Expert Review of Pharmacoeconomics & Outcomes Research. 20(4). 321–330. 14 indexed citations

15.

Vreman, Rick A., et al.. (2020). Application of Managed Entry Agreements for Innovative Therapies in Different Settings and Combinations: A Feasibility Analysis. International Journal of Environmental Research and Public Health. 17(22). 8309–8309. 27 indexed citations

16.

Vreman, Rick A., Svetlana V. Belitser, Anke M. Hövels, et al.. (2020). Efficacy gap between phase II and subsequent phase III studies in oncology. British Journal of Clinical Pharmacology. 86(7). 1306–1313. 10 indexed citations

17.

Vreman, Rick A., Huseyin Naci, Wim Goettsch, et al.. (2020). Decision Making Under Uncertainty: Comparing Regulatory and Health Technology Assessment Reviews of Medicines in the United States and Europe. Clinical Pharmacology & Therapeutics. 108(2). 350–357. 52 indexed citations

18.

Makady, Amr, et al.. (2019). The implementation of HTA in medicine pricing and reimbursement policies in Indonesia: Insights from multiple stakeholders. PLoS ONE. 14(11). e0225626–e0225626. 6 indexed citations

19.

Makady, Amr, et al.. (2019). Use of medicine pricing and reimbursement policies for universal health coverage in Indonesia. PLoS ONE. 14(2). e0212328–e0212328. 18 indexed citations

20.

Vreman, Rick A., et al.. (2019). Phase I/II Clinical Trial-Based Early Economic Evaluation of Acalabrutinib for Relapsed Chronic Lymphocytic Leukaemia. Applied Health Economics and Health Policy. 17(6). 883–893. 14 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact